Kleijn Tony G, Ameline Baptiste, Schreuder Willem H, Szuhai Károly, Kooistra Wierd, van Kempen Léon, Japalagh Ghazaleh S H, Briaire-de Bruijn Inge H, van der Meeren Stijn W, Kleijwegt Maarten C, Witjes Max, Pichardo Sarina E C, van Furth Wouter R, Lausová Tereza, Breimer Gerben E, Braunius Weibel, de Lange Jan, van Langevelde Kirsten, Kroon Herman M, van den Hout Mari F C M, Koppes Sjors A, Haefliger Simon, Ooft Marc L, van Engen-van Grunsven Ilse C H, Flucke Uta E, Hiemcke-Jiwa Laura, Savci-Heijink Dilara C, Diercks Gilles F H, Doff Jan J, Suurmeijer Albert J H, Bovée Judith V M G, von Deimling Andreas, Baumhoer Daniel, Cleven Arjen H G
Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, the Netherlands.
Bone Tumor Reference Centre at the Institute for Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Mod Pathol. 2025 Jun;38(6):100717. doi: 10.1016/j.modpat.2025.100717. Epub 2025 Jan 23.
Fibro-osseous tumors of the craniofacial bones are a heterogeneous group of lesions comprising cemento-osseous dysplasia (COD), cemento-ossifying fibroma (COF), juvenile trabecular ossifying fibroma (JTOF), psammomatoid ossifying fibroma (PsOF), fibrous dysplasia (FD), and low-grade osteosarcoma (LGOS) with overlapping clinicopathological features. However, their clinical behavior and treatment differ significantly, underlining the need for accurate diagnosis. Molecular diagnostic markers exist for subsets of these tumors, including GNAS mutations in FD, SATB2 fusions in PsOF, mutations involving the RAS-MAPK signaling pathway in COD, and MDM2 amplification in LGOS. Because DNA methylation and copy number profiling are well established for the classification of central nervous system tumors, we aimed to investigate whether this tool might be used as well for classifying fibro-osseous tumors in the craniofacial bones. We collected a well-characterized, multicenter cohort with available molecular data, including COD (n = 20), COF (n = 13), JTOF (n = 10), PsOF (n = 25), FD (n = 23), LGOS (n = 4), and high-grade osteosarcoma (HGOS; n = 11). Genome-wide DNA methylation and copy number variation data were generated using the Illumina Infinium Methylation EPIC array interrogating >850 000 CpG sites. DNA methylation profiling yielded evaluable results in 73/106 tumors, including 6 CODs, 12 COFs, 6 JTOFs, 19 PsOFs, 18 FDs, 2 LGOSs, and 10 HGOSs. Unsupervised clustering and dimensionality reduction (Uniform Manifold Approximation and Projection) revealed that FD, extragnatic PsOF, and HGOS formed distinct clusters. Surprisingly, COD, COF, JTOF, and mandibular PsOF clustered together, apart from other craniofacial bone tumors. LGOS did not form a distinct cluster, likely due to the low number of cases. Copy number analysis revealed that FD, COD, COF, JTOF, and PsOF were typically characterized by flat copy number profiles compared with LGOS with gains of chromosome 12 and HGOS with multiple heterogeneous copy number alterations. In conclusion, using DNA methylation and copy number profiles, benign fibro-osseous tumors can be separated from low-grade and HGOSs in the craniofacial bones, which is of diagnostic value in challenging cases with overlapping clinicopathological features.
颅面骨的纤维-骨肿瘤是一组异质性病变,包括牙骨质-骨发育异常(COD)、牙骨质化纤维瘤(COF)、青少年小梁骨化纤维瘤(JTOF)、砂粒体样骨化纤维瘤(PsOF)、骨纤维异常增殖症(FD)和低级别骨肉瘤(LGOS),它们具有重叠的临床病理特征。然而,它们的临床行为和治疗方法有显著差异,这突出了准确诊断的必要性。这些肿瘤的某些亚组存在分子诊断标志物,包括FD中的GNAS突变、PsOF中的SATB2融合、COD中涉及RAS-MAPK信号通路的突变以及LGOS中的MDM2扩增。由于DNA甲基化和拷贝数分析在中枢神经系统肿瘤分类中已得到广泛应用,我们旨在研究该工具是否也可用于颅面骨纤维-骨肿瘤的分类。我们收集了一个特征明确的多中心队列,其中包含可用的分子数据,包括COD(n = 20)、COF(n = 13)、JTOF(n = 10)、PsOF(n = 25)、FD(n = 23)、LGOS(n = 4)和高级别骨肉瘤(HGOS;n = 11)。使用Illumina Infinium Methylation EPIC芯片检测超过85万个CpG位点,生成全基因组DNA甲基化和拷贝数变异数据。DNA甲基化分析在106个肿瘤中的73个产生了可评估结果,包括6个COD、12个COF、6个JTOF、19个PsOF、18个FD、2个LGOS和10个HGOS。无监督聚类和降维(均匀流形逼近和投影)显示,FD、颌外PsOF和HGOS形成了不同的聚类。令人惊讶的是,COD、COF、JTOF和下颌PsOF聚集在一起,与其他颅面骨肿瘤不同。LGOS没有形成一个明显的聚类,可能是因为病例数较少。拷贝数分析显示,与具有12号染色体增益的LGOS和具有多个异质性拷贝数改变的HGOS相比,FD、COD、COF、JTOF和PsOF通常具有平坦的拷贝数谱。总之,利用DNA甲基化和拷贝数谱,可以将颅面骨的良性纤维-骨肿瘤与低级别和高级别骨肉瘤区分开来,这对于具有重叠临床病理特征的疑难病例具有诊断价值。